IO BIOTECH INC. - COMMON STOCK

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

26 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

25 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

25 Mar 2025 16:35:00 By Nasdaq GlobeNewswire

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

18 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Reports 2024 Business Highlights

04 Mar 2025 16:17:04 By Nasdaq GlobeNewswire

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

23 Feb 2025 12:07:39 By Nasdaq GlobeNewswire

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

20 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

04 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

09 Jan 2025 08:05:00 By Nasdaq GlobeNewswire

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

20 Dec 2024 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

12 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

07 Nov 2024 10:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

14 Sep 2024 02:30:00 By Nasdaq GlobeNewswire

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

30 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

26 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

13 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

25 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

IO Biotech to Present at Jefferies Global Healthcare Conference

23 May 2024 08:30:00 By Nasdaq GlobeNewswire